VYNE Finalizes Merger With Yarrow, Pays Dividend; To Trade On 1-for-50 Split Basis; Stock Plunges
VYNE Therapeutics said it distributed a special cash dividend to holders of record July 22, 2026, paid July 23, subject to Nasdaq due bill procedures, ahead of a planned 1-for-50 reverse split effective July 24 and split-adjusted trading July 27. VYNE expects merger closing with Yarrow Bioscience early in the week of July 27, with the combined company trading as YARW. VYNE closed at $0.9234.
How this was made
The 30-second read
Why it matters
The key tradable elements are the ex-dividend date (July 24), reverse split effective date (July 24) with split-adjusted trading starting July 27, and an updated expectation for merger closing early in the week of July 27 pending Nasdaq listing application review.
Market read
Near-term trading is likely driven by corporate-action mechanics (due-bills, ex-dividend, reverse split) and the probability-weighted timing of merger close around July 27.
What to watch
Due-bill obligations during July 21-23 can distort near-term price signals; traders should account for settlement effects and the Nasdaq listing approval dependency for the merger close.
Background
VYNE linked a special cash dividend and a proposed merger with Yarrow Bioscience to a planned 1-for-50 reverse stock split and Nasdaq due-bill procedures.
Ticker impact
VYNE announced its special cash dividend payment tied to the proposed Yarrow merger and a planned 1-for-50 reverse split.
Elevated volatility around July 24 ex-dividend and July 27 split-adjusted trading, with direction likely driven by merger close expectations rather than the dividend itself.
The article provides concrete dates for dividend payment, ex-dividend, reverse split effective date, and expected merger closing window, which can affect liquidity, due-bill pricing, and investor positioning.
Market effects
Limited direct read-across; this is primarily company-specific corporate action and deal-timing execution.
US Nasdaq microcap/small-cap trading mechanics (due-bills, reverse split) may affect local liquidity and short-term sentiment.
Low; no cross-border operational or regulatory developments described.
Counterpoint
The dividend and reverse split mechanics may be largely technical, so the pre-market drop could reflect deal risk or broader sentiment rather than the corporate actions themselves.
Key entities
- public_companyVYNE Therapeutics Inc.
Announced special cash dividend payment, reverse split timing, and updated expected merger closing window with Yarrow.
- public_companyYarrow Bioscience, Inc.
Expected to be the operating company post-merger and trade on Nasdaq under ticker YARW.
- deal_entityYellow Merger Sub Corp.
Merger subsidiary referenced in the proposed transaction structure.
